Prevention of End Stage Kidney Disease by Darbepoetin Alfa In CKD Patients With Non-diabetic Kidney Disease
Anemia is common among patients with chronic kidney disease (CKD) and is associated with an
increased risk of cardiovascular and renal events. Although erythropoiesis stimulating agent
(ESA) has been used to correct anemia, use of ESA (hemoglobin level at approximately 13
g/dL) did not reduce cardiovascular or renal events in diabetic CKD patients. Subgroup
analysis of a recent randomized study suggested that use of darbepoetin alfa targeting Hb
between 11 and 13 g/dL may preserve renal function better than targeting Hb between 9 and
11g/dL in non-diabetic CKD patients.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.
Japan: Institutinal Review Board, Showa University School of Medicine